Novo Nordisk Advances New First‑in‑Human Obesity Drug NNC6989‑0001 Into Testing
Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novo Nordisk (NVO) has started a first‑in‑human study of a new obesity drug called NNC6989‑0001. The official aim is to test safety, tolerability, and how the drug moves and acts in the body after single and repeated doses in healthy adults with overweight or obesity, an early but important step that could expand the company’s long‑term obesity pipeline.
The study tests an experimental drug, NNC6989‑0001 A, against a placebo that looks the same. The goal is to see if the new treatment is safe and well tolerated while showing early signs that it may help manage weight in people living with overweight or obesity.
This is a Phase 1 interventional study where participants are randomly assigned to either the active drug or placebo. It is quadruple‑masked, which means participants, doctors, study staff, and outcome assessors do not know who receives NNC6989‑0001, helping reduce bias, and the main goal is treatment development rather than direct patient benefit.
The trial was first submitted on Feb. 20, 2026, signaling the official launch of this early program. The most recent update on Feb. 26, 2026, confirms that the study status is recruiting, with primary and final completion dates still to be determined as data from early dosing cohorts accumulate.
For investors, this update underlines Novo Nordisk’s push to deepen its obesity franchise beyond current blockbusters like Wegovy. Phase 1 data are years away from market impact, but continued pipeline investment can support sentiment and valuation, especially as rivals such as Eli Lilly and others race to expand their own obesity and metabolic portfolios.
The study is active and recruiting, with ongoing updates and detailed information available on the ClinicalTrials.gov portal under ID NCT07437079.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.
